{"entity":{"type":"insider","cik":"0001930214","url":"/insider/0001930214","json_url":"/insider/0001930214.json","name":"Vivo Opportunity Fund Holdings, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":65,"n_filings":13,"first":"2022-08-16","last":"2026-07-16","span_basis":"filed_date"},"name_variants":[{"name":"Vivo Opportunity Fund Holdings, L.P.","source":"filing","n_filings":13,"first_seen":"2022-08-16","last_seen":"2026-07-16"}],"transactions":[{"id":6006965,"accession":"0001213900-26-078891","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-26-078891","line_url":"/filing/0001213900-26-078891","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Cayman, LLC; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC","owner_display_name":"Vivo Opportunity Cayman Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21.0,"shares_display":"21","price_per_share":1.55,"price_display":"1.55","price_state":"stated","total_value":32.55,"total_display":"32.55","total_whole":"33","shares_owned_after":743057.0,"shares_owned_after_display":"743,057","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-16","filed_date":"2026-07-16","scope":"insider","n_lines":2},{"id":6006961,"accession":"0001213900-26-078891","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-26-078891","line_url":"/filing/0001213900-26-078891","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Cayman, LLC; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC","owner_display_name":"Vivo Opportunity Cayman Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15150.0,"shares_display":"15,150","price_per_share":1.55,"price_display":"1.55","price_state":"stated","total_value":23482.5,"total_display":"23,482.50","total_whole":"23,483","shares_owned_after":743038.0,"shares_owned_after_display":"743,038","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-15","filed_date":"2026-07-16","scope":"insider","n_lines":2},{"id":6006957,"accession":"0001213900-26-078891","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-26-078891","line_url":"/filing/0001213900-26-078891","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Cayman, LLC; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC","owner_display_name":"Vivo Opportunity Cayman Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5375.0,"shares_display":"5,375","price_per_share":1.55,"price_display":"1.55","price_state":"stated","total_value":8331.25,"total_display":"8,331.25","total_whole":"8,331","shares_owned_after":729277.0,"shares_owned_after_display":"729,277","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-14","filed_date":"2026-07-16","scope":"insider","n_lines":2},{"id":5810974,"accession":"0001213900-26-075144","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-26-075144","line_url":"/filing/0001213900-26-075144","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Cayman, LLC","owner_display_name":"Vivo Opportunity Fund Holdings, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1607.0,"shares_display":"1,607","price_per_share":1.55,"price_display":"1.55","price_state":"stated","total_value":2490.85,"total_display":"2,490.85","total_whole":"2,491","shares_owned_after":724395.0,"shares_owned_after_display":"724,395","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-02","filed_date":"2026-07-02","scope":"insider","n_lines":2},{"id":5810970,"accession":"0001213900-26-075144","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-26-075144","line_url":"/filing/0001213900-26-075144","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Cayman, LLC","owner_display_name":"Vivo Opportunity Fund Holdings, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4344.0,"shares_display":"4,344","price_per_share":1.55,"price_display":"1.55","price_state":"stated","total_value":6733.2,"total_display":"6,733.20","total_whole":"6,733","shares_owned_after":722935.0,"shares_owned_after_display":"722,935","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-02","scope":"insider","n_lines":2},{"id":5810968,"accession":"0001213900-26-075144","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-26-075144","line_url":"/filing/0001213900-26-075144","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Cayman, LLC","owner_display_name":"Vivo Opportunity Fund Holdings, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":600.0,"shares_display":"600","price_per_share":1.54,"price_display":"1.54","price_state":"stated","total_value":924.0,"total_display":"924.00","total_whole":"924","shares_owned_after":718989.0,"shares_owned_after_display":"718,989","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-30","filed_date":"2026-07-02","scope":"insider","n_lines":2},{"id":5798837,"accession":"0001213900-26-067505","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0001213900-26-067505","line_url":"/filing/0001213900-26-067505","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman, LLC; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity Cayman, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":32500.0,"shares_display":"32,500","price_per_share":1.52,"price_display":"1.52","price_state":"stated","total_value":49400.0,"total_display":"49,400.00","total_whole":"49,400","shares_owned_after":718444.0,"shares_owned_after_display":"718,444","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-08","filed_date":"2026-06-10","scope":"insider","n_lines":2},{"id":5798820,"accession":"0001213900-26-067505","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0001213900-26-067505","line_url":"/filing/0001213900-26-067505","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman, LLC; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity Cayman, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55011.0,"shares_display":"55,011","price_per_share":1.57,"price_display":"1.57","price_state":"stated","total_value":86367.27,"total_display":"86,367.27","total_whole":"86,367","shares_owned_after":688926.0,"shares_owned_after_display":"688,926","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-05","filed_date":"2026-06-10","scope":"insider","n_lines":2},{"id":5798816,"accession":"0001213900-26-067505","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001213900-26-067505","line_url":"/filing/0001213900-26-067505","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman, LLC; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity Cayman, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6743.0,"shares_display":"6,743","price_per_share":1.57,"price_display":"1.57","price_state":"stated","total_value":10586.51,"total_display":"10,586.51","total_whole":"10,587","shares_owned_after":638960.0,"shares_owned_after_display":"638,960","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-04","filed_date":"2026-06-10","scope":"insider","n_lines":2},{"id":5798814,"accession":"0001213900-26-067505","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001213900-26-067505","line_url":"/filing/0001213900-26-067505","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman, LLC; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity Cayman, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7783.0,"shares_display":"7,783","price_per_share":1.55,"price_display":"1.55","price_state":"stated","total_value":12063.65,"total_display":"12,063.65","total_whole":"12,064","shares_owned_after":632835.0,"shares_owned_after_display":"632,835","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-03","filed_date":"2026-06-10","scope":"insider","n_lines":2},{"id":5798810,"accession":"0001213900-26-067505","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001213900-26-067505","line_url":"/filing/0001213900-26-067505","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman, LLC; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity Cayman, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":22848.0,"shares_display":"22,848","price_per_share":1.52,"price_display":"1.52","price_state":"stated","total_value":34728.96,"total_display":"34,728.96","total_whole":"34,729","shares_owned_after":625766.0,"shares_owned_after_display":"625,766","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-02","filed_date":"2026-06-10","scope":"insider","n_lines":2},{"id":5798807,"accession":"0001213900-26-067505","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001213900-26-067505","line_url":"/filing/0001213900-26-067505","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman, LLC; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity Cayman, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16336.0,"shares_display":"16,336","price_per_share":1.55,"price_display":"1.55","price_state":"stated","total_value":25320.8,"total_display":"25,320.80","total_whole":"25,321","shares_owned_after":605013.0,"shares_owned_after_display":"605,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-01","filed_date":"2026-06-10","scope":"insider","n_lines":2},{"id":5798804,"accession":"0001213900-26-067505","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-26-067505","line_url":"/filing/0001213900-26-067505","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman, LLC; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity Cayman, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17796.0,"shares_display":"17,796","price_per_share":1.57,"price_display":"1.57","price_state":"stated","total_value":27939.72,"total_display":"27,939.72","total_whole":"27,940","shares_owned_after":590175.0,"shares_owned_after_display":"590,175","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-29","filed_date":"2026-06-10","scope":"insider","n_lines":2},{"id":5798798,"accession":"0001213900-26-067505","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-26-067505","line_url":"/filing/0001213900-26-067505","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman, LLC; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity Cayman, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":34000.0,"shares_display":"34,000","price_per_share":1.69,"price_display":"1.69","price_state":"stated","total_value":57460.0,"total_display":"57,460.00","total_whole":"57,460","shares_owned_after":574011.0,"shares_owned_after_display":"574,011","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-21","filed_date":"2026-06-10","scope":"insider","n_lines":2},{"id":5798794,"accession":"0001213900-26-067505","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-26-067505","line_url":"/filing/0001213900-26-067505","is_derivative":false,"issuer_cik":"0001728328","issuer_name":"InMed Pharmaceuticals Inc.","issuer_ticker":"INM","issuer_name_source":null,"issuer_url":"/issuer/0001728328","owner_cik":null,"owner_name":"Vivo Opportunity Cayman, LLC; Vivo Opportunity, LLC; Vivo Opportunity Cayman Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity Cayman, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":56210.0,"shares_display":"56,210","price_per_share":1.56,"price_display":"1.56","price_state":"stated","total_value":87687.6,"total_display":"87,687.60","total_whole":"87,688","shares_owned_after":543129.0,"shares_owned_after_display":"543,129","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-20","filed_date":"2026-06-10","scope":"insider","n_lines":2},{"id":5119314,"accession":"0001013762-25-004322","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001013762-25-004322","line_url":"/filing/0001013762-25-004322#line-3","is_derivative":false,"issuer_cik":"0001484565","issuer_name":"SOLENO THERAPEUTICS INC","issuer_ticker":"SLNO","issuer_name_source":null,"issuer_url":"/issuer/0001484565","owner_cik":null,"owner_name":"Vivo Opportunity, LLC; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":333557.0,"shares_display":"333,557","price_per_share":70.6,"price_display":"70.60","price_state":"stated","total_value":23549124.2,"total_display":"23,549,124.20","total_whole":"23,549,124","shares_owned_after":4458294.0,"shares_owned_after_display":"4,458,294","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-28","filed_date":"2025-03-28","scope":"insider"},{"id":5119310,"accession":"0001013762-25-004322","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001013762-25-004322","line_url":"/filing/0001013762-25-004322#line-2","is_derivative":false,"issuer_cik":"0001484565","issuer_name":"SOLENO THERAPEUTICS INC","issuer_ticker":"SLNO","issuer_name_source":null,"issuer_url":"/issuer/0001484565","owner_cik":null,"owner_name":"Vivo Opportunity, LLC; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1100000.0,"shares_display":"1,100,000","price_per_share":67.8,"price_display":"67.80","price_state":"stated","total_value":74580000.0,"total_display":"74,580,000.00","total_whole":"74,580,000","shares_owned_after":4791851.0,"shares_owned_after_display":"4,791,851","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-27","filed_date":"2025-03-28","scope":"insider"},{"id":5119306,"accession":"0001013762-25-004322","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001013762-25-004322","line_url":"/filing/0001013762-25-004322#line-1","is_derivative":false,"issuer_cik":"0001484565","issuer_name":"SOLENO THERAPEUTICS INC","issuer_ticker":"SLNO","issuer_name_source":null,"issuer_url":"/issuer/0001484565","owner_cik":null,"owner_name":"Vivo Opportunity, LLC; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400000.0,"shares_display":"400,000","price_per_share":65.8,"price_display":"65.80","price_state":"stated","total_value":26320000.0,"total_display":"26,320,000.00","total_whole":"26,320,000","shares_owned_after":5891851.0,"shares_owned_after_display":"5,891,851","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-26","filed_date":"2025-03-28","scope":"insider"},{"id":2944685,"accession":"0001213900-24-074051","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-24-074051","line_url":"/filing/0001213900-24-074051#line-3","is_derivative":false,"issuer_cik":"0001484565","issuer_name":"SOLENO THERAPEUTICS INC","issuer_ticker":"SLNO","issuer_name_source":null,"issuer_url":"/issuer/0001484565","owner_cik":null,"owner_name":"Vivo Opportunity, LLC; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":47.22,"price_display":"47.22","price_state":"stated","total_value":4722000.0,"total_display":"4,722,000.00","total_whole":"4,722,000","shares_owned_after":6291851.0,"shares_owned_after_display":"6,291,851","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-29","filed_date":"2024-08-29","scope":"insider"},{"id":2944678,"accession":"0001213900-24-074051","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-24-074051","line_url":"/filing/0001213900-24-074051#line-2","is_derivative":false,"issuer_cik":"0001484565","issuer_name":"SOLENO THERAPEUTICS INC","issuer_ticker":"SLNO","issuer_name_source":null,"issuer_url":"/issuer/0001484565","owner_cik":null,"owner_name":"Vivo Opportunity, LLC; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":425000.0,"shares_display":"425,000","price_per_share":47.35,"price_display":"47.35","price_state":"stated","total_value":20123750.0,"total_display":"20,123,750.00","total_whole":"20,123,750","shares_owned_after":6391851.0,"shares_owned_after_display":"6,391,851","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-28","filed_date":"2024-08-29","scope":"insider"},{"id":2944673,"accession":"0001213900-24-074051","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-24-074051","line_url":"/filing/0001213900-24-074051#line-1","is_derivative":false,"issuer_cik":"0001484565","issuer_name":"SOLENO THERAPEUTICS INC","issuer_ticker":"SLNO","issuer_name_source":null,"issuer_url":"/issuer/0001484565","owner_cik":null,"owner_name":"Vivo Opportunity, LLC; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Opportunity, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":48.73,"price_display":"48.73","price_state":"stated","total_value":24365000.0,"total_display":"24,365,000.00","total_whole":"24,365,000","shares_owned_after":6816851.0,"shares_owned_after_display":"6,816,851","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-27","filed_date":"2024-08-29","scope":"insider"},{"id":2383108,"accession":"0001213900-24-038343","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-24-038343","line_url":"/filing/0001213900-24-038343#line-2","is_derivative":false,"issuer_cik":"0001484565","issuer_name":"SOLENO THERAPEUTICS INC","issuer_ticker":"SLNO","issuer_name_source":null,"issuer_url":"/issuer/0001484565","owner_cik":null,"owner_name":"Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC","owner_display_name":"Vivo Opportunity Fund Holdings, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":351242.0,"shares_display":"351,242","price_per_share":45.13,"price_display":"45.13","price_state":"stated","total_value":15851551.46,"total_display":"15,851,551.46","total_whole":"15,851,551","shares_owned_after":7316851.0,"shares_owned_after_display":"7,316,851","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-30","filed_date":"2024-05-01","scope":"insider"},{"id":2383104,"accession":"0001213900-24-038343","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-24-038343","line_url":"/filing/0001213900-24-038343#line-1","is_derivative":false,"issuer_cik":"0001484565","issuer_name":"SOLENO THERAPEUTICS INC","issuer_ticker":"SLNO","issuer_name_source":null,"issuer_url":"/issuer/0001484565","owner_cik":null,"owner_name":"Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC","owner_display_name":"Vivo Opportunity Fund Holdings, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750000.0,"shares_display":"750,000","price_per_share":47.8,"price_display":"47.80","price_state":"stated","total_value":35850000.0,"total_display":"35,850,000.00","total_whole":"35,850,000","shares_owned_after":7668093.0,"shares_owned_after_display":"7,668,093","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-29","filed_date":"2024-05-01","scope":"insider"},{"id":2093075,"accession":"0001213900-24-030020","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001213900-24-030020","line_url":"/filing/0001213900-24-030020","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":138066.0,"shares_display":"138,066","price_per_share":6.2,"price_display":"6.20","price_state":"stated","total_value":856009.2,"total_display":"856,009.20","total_whole":"856,009","shares_owned_after":4023741.0,"shares_owned_after_display":"4,023,741","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-03","filed_date":"2024-04-03","scope":"insider","n_lines":3},{"id":2093069,"accession":"0001213900-24-030020","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-24-030020","line_url":"/filing/0001213900-24-030020","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":101480.0,"shares_display":"101,480","price_per_share":6.65,"price_display":"6.65","price_state":"stated","total_value":674842.0,"total_display":"674,842.00","total_whole":"674,842","shares_owned_after":4127611.0,"shares_owned_after_display":"4,127,611","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-02","filed_date":"2024-04-03","scope":"insider","n_lines":3},{"id":2093063,"accession":"0001213900-24-030020","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-24-030020","line_url":"/filing/0001213900-24-030020","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":181117.0,"shares_display":"181,117","price_per_share":6.99,"price_display":"6.99","price_state":"stated","total_value":1266007.83,"total_display":"1,266,007.83","total_whole":"1,266,008","shares_owned_after":4203957.0,"shares_owned_after_display":"4,203,957","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-01","filed_date":"2024-04-03","scope":"insider","n_lines":3},{"id":8024134,"accession":"0001213900-23-089692","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-23-089692","line_url":"/filing/0001213900-23-089692","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Panda Fund, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.; Vivo Panda, LLC; Vivo Opportunity, LLC; Vivo Capital VIII, LLC","owner_display_name":"Vivo Panda Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3400.0,"shares_display":"3,400","price_per_share":0.9,"price_display":"0.90","price_state":"stated","total_value":3060.0,"total_display":"3,060.00","total_whole":"3,060","shares_owned_after":1952302.0,"shares_owned_after_display":"1,952,302","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-21","filed_date":"2023-11-22","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":"2023-11-21|8024130","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001728328","name":"InMed Pharmaceuticals Inc.","url":"/issuer/0001728328","role":"Ten percent owner","n_filings":3,"first_seen":"2026-06-10","last_seen":"2026-07-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001484565","name":"SOLENO THERAPEUTICS INC","url":"/issuer/0001484565","role":"Ten percent owner","n_filings":3,"first_seen":"2024-05-01","last_seen":"2025-03-28"},{"type":"issuer","type_label":"ISSUER","cik":"0001831363","name":"Terns Pharmaceuticals, Inc.","url":"/issuer/0001831363","role":"Ten percent owner","n_filings":4,"first_seen":"2022-08-16","last_seen":"2024-04-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001641281","name":"Bolt Biotherapeutics, Inc.","url":"/issuer/0001641281","role":"Ten percent owner","n_filings":2,"first_seen":"2023-11-20","last_seen":"2023-11-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001865494","name":"IO Biotech, Inc.","url":"/issuer/0001865494","role":"Ten percent owner","n_filings":1,"first_seen":"2023-08-10","last_seen":"2023-08-10"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001930214","retrieved_at":"2026-08-23T07:09:02+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}